SOURCE: StockCall


October 22, 2010 09:04 ET

Opinions on Abbott Laboratories and Johnson & Johnson -- A Brief Overview of the Major Drug Makers Space

JOHANNESBURG, SOUTH AFRICA--(Marketwire - October 22, 2010) - offers investors comprehensive research on the drug manufacturers - major industry and has completed analytical research on Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ). Register with us today at to have free access to these researches.

Recent earnings reports released by companies in the Drug Manufacturers - Major industry have been mixed. While companies that have more diversified products are handling the recent rash of patent expires better, there are still other factors at play. is an online platform where investors doing their due-diligence on the drug manufacturers - major industry can have easy and free access to our analyst research and opinions on Abbott Laboratories and Johnson & Johnson; all investors need to do is register for a complimentary membership at

Some companies have recently been dealing with costly recalls on some of their products. Recalls themselves are expensive but the damage to a company's name due to a decline in consumer confidence can prove to be even more of a detriment. Register now at to have free access to our reports on the drug manufacturers - major industry.

For those in the industry that are doing well, expansion into global markets and successful research and development are being seen as some of the key reasons for this. Companies are now in various stages of progress in finding treatments for kidney and arthritic problems as well as HIV to name a few. Shrewd expansion and investment abroad is also helping keep companies in the black with global sales for some reaching double digits figures. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

For the industry so far, Abbott Laboratories and Johnson & Johnson have already posted their earnings for this quarter during this week. Abbott Laboratories posted a 40% decline in its quarterly earnings due to costs linked to layoffs, a baby-formula recall and the removal of a diet drug on grounds of safety concerns. Investors looking for free research on Abbott Laboratories are welcome to sign up at

On the other hand, Johnson & Johnson posted its results a day before Abbott with profits of $3.42 billion on a slight dip in revenue as compared to the same quarter in 2009 that is revenue of $14.98 billion. Here again recalls influenced results even though it was not the only factor impacting revenue negatively. Investors looking for free research on Johnson & Johnson are welcome to sign up at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information